In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody

Iriki H, Takahashi H, Amagai M. Diverse role of OX40 on T cells as a therapeutic target for skin diseases. J Invest Dermatol 2023; 143: 545–553. DOI: https://doi.org/10.1016/j.jid.2022.11.009

Sadrolashrafi K, Guo L, Kikuchi R, Hao A, Yamamoto RK, Tolson HC, et al. An OX-Tra’Ordinary tale: the role of OX40 and OX40L in atopic dermatitis. Cells 2024; 13. DOI: https://doi.org/10.3390/cells13070587

Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol 2023; 189: 531–539. DOI: https://doi.org/10.1093/bjd/ljad240

Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2025; 155: 1264–1275. DOI: https://doi.org/10.1016/j.jaci.2024.10.031

Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005. Clin Pharmacol Ther 2022; 111: 1121–1132. DOI: https://doi.org/10.1002/cpt.2539

Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 2023; 401: 204–214. DOI: https://doi.org/10.1016/S0140-6736(22)02037-2

Rewerska B, Sher LD, Alpizar S, Pauser S, Pulka G, Mozaffarian N, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Glob 2024; 3: 100195. 63 DOI: https://doi.org/10.1016/j.jacig.2023.100195

Silva JP, Vetterlein O, Jose J, Peters S, Kirby H. The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm ex-change as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem 2015; 290: 5462–5469. DOI: https://doi.org/10.1074/jbc.M114.600973

Crescioli S, Correa I, Karagiannis P, Davies AM, Sutton BJ, Nestle FO, et al. IgG4 characteristics and functions in cancer immunity. Curr Allergy Asthma Rep 2016; 16: 7. DOI: https://doi.org/10.1007/s11882-015-0580-7

Zahavi D, AlDeghaither D, O’Connell A, Weiner LM. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther 2018; 1: 7–12. DOI: https://doi.org/10.1093/abt/tby002

Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Rev Immunol 2023; 23: 763–778. DOI: https://doi.org/10.1038/s41577-023-00871-z

Guttman-Yassky E, Croft M, Geng B, Rynkiewicz N, Lucchesi D, Peakman M, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. Br J Dermatol 2024; 191: 488–496. DOI: https://doi.org/10.1093/bjd/ljae230

Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 2021; 148: 927–940. DOI: https://doi.org/10.1016/j.jaci.2021.08.009

Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 144: 482–493 e487. DOI: https://doi.org/10.1016/j.jaci.2018.11.053

Martin A, Tisch RM, Getts DR. Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy. Clin Immunol 2013; 148: 136–147. DOI: https://doi.org/10.1016/j.clim.2013.04.011